Source - RNS
RNS Number : 4045X
Scancell Holdings Plc
10 August 2018

10 August 2018


Scancell Holdings Plc

("Scancell" or the "Company")


Board Change



Scancell Holdings Plc (AIM: SCLP) today announces that Kate Cornish-Bowden will be stepping down as Non-Executive Director as of 31 August 2018 after seven years on the Board of the Company.  


Dr John Chiplin, Chairman of Scancell, commented:


"Kate has made an important contribution in guiding Scancell through its formative years during her time on the Board and in her role as chairman of the Remuneration Committee. We would like to thank her for her hard work and wish her all the best for the future."



For Further Information:


Scancell Holdings Plc



Dr John Chiplin, Chairman


+44 (0) 20 3727 1000

Dr Cliff Holloway, CEO






Panmure Gordon (UK) Limited

(Nominated Adviser and Corporate broker)



Freddy Crossley/Emma Earl


+44 (0) 20 7886 2500




FTI Consulting

Mo Noonan/Simon Conway


+44 (0) 20 3727 1000



About Scancell


Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.


ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival. 


·     SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.


·     SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2. 


Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.


·      Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.


For further details, please see our website:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit